Rationalizing the development of live attenuated virus vaccines

Nature Biotechnology

Volumn 28, Issue 6, 2010, Pages 573-579

  Lauring, Adam S ^a   Jones, Jeremy O ^a   Andino, Raul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPIRICAL ATTENUATION; GENE MUTATIONS; HUMAN TESTING; INACTIVATED VIRUS; MICRORNAS; SAFETY ISSUES; SUBUNIT VACCINE; VIRAL DISEASE; VIRAL REPLICATION; ZINC FINGER;

VACCINES; ZINC;

VIRUSES;

INACTIVATED VIRUS VACCINE; LIVE VACCINE; MICRORNA; SUBUNIT VACCINE; VIRUS VACCINE; ZINC FINGER PROTEIN;

CODON; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE REPLICATION; MEASLES; MUMPS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SMALLPOX; VACCINATION; VIROLOGY; VIRUS ATTENUATION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS VIRULENCE; YELLOW FEVER;

GENE DELETION; HUMANS; MICRORNAS; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES; ZINC FINGERS;

HUMAN IMMUNODEFICIENCY VIRUS 1; VARIOLA VIRUS;

EID: 77953249856     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1635     Document Type: Review

References (69)

1. Salk, J. Polio vaccines and polioviruses. BMJ 2, 765 (1977).
2. Arvin, A.M. & Greenberg, H.B. New viral vaccines. Virology 344, 240-249 (2006).
3. Rogan, D. & Babiuk, L.A. Novel vaccines from biotechnology. Rev. Sci. Tech. 24, 159-174 (2005).
4. Kersten, G.F. & Crommelin, D.J. Liposomes and ISCOMs. Vaccine 21, 915-920 (2003).
5. Jennings, G.T. & Bachmann, M.F. The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521-536 (2008).
6. Felnerova, D., Viret, J.F., Gluck, R. & Moser, C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15, 518-529 (2004).
7. Panicali, D. & Paoletti, E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA 79, 4927-4931 (1982).
8. Dudek, T. & Knipe, D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239 (2006).
9. Loudon, P.T. et al. Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J. Gene Med. 3, 458-467 (2001).
10. Nguyen, L.H., Knipe, D.M. & Finberg, R.w. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66, 7067-7072 (1992).
11. Morrison, L.A. & Knipe, D.M. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 220, 402-413 (1996).
12. Da Costa, X., Kramer, M.F., Zhu, J., Brockman, M.A. & Knipe, D.M. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J. Virol. 74, 7963-7971 (2000).
13. Hoshino, Y. et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79, 410-418 (2005).
14. Da Costa, X.J., Jones, C.A. & Knipe, D.M. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl. Acad. Sci. USA 96, 6994-6998 (1999).
15. McLean, C.S. et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170, 1100-1109 (1994).
16. Farrell, H.E. et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 68, 927-932 (1994).
17. watanabe, T., watanabe, S., Neumann, G., Kida, H. & Kawaoka, Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76, 767-773 (2002).
18. Stech, J. Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines. Expert Rev. Vaccines 7, 739-743 (2008)
19. widman, D.G., Frolov, I. & Mason, P.w. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv. Virus Res. 72, 77-126 (2008).
20. Holland, J. et al. Rapid evolution of RNA genomes. Science 215, 1577-1585 (1982).
21. Vignuzzi, M., Stone, J.K. & Andino, R. Ribavirin and lethal mutagenesis of poliovi-rus: molecular mechanisms, resistance and biological implications. Virus Res. 107, 173-181 (2005)
22. walker, B.D. & Burton, D. Toward an AIDS vaccine. Science 320, 760-764 (2008).
23. Couch, R.B. Seasonal inactivated influenza virus vaccines. Vaccine 26 Suppl 4, D5-D9 (2008).
24. Minor, P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27, 2649-2652 (2009).
25. Domingo, E. et al. Viruses as quasispecies: biological implications. Curr. Top. Microbiol. Immunol. 299, 51-82 (2006).
26. Biebricher, C.K. & Eigen, M. The error threshold. Virus Res. 107, 117-127 (2005).
27. Arnold, J.J., Vignuzzi, M., Stone, J.K., Andino, R. & Cameron, C.E. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280, 25706-25716 (2005).
28. Pfeiffer, J.K. & Kirkegaard, K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA 100, 7289-7294 (2003).
29. Sierra, M. et al. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81, 2012-2024 (2007).
30. Vignuzzi, M., Stone, J.K., Arnold, J.J., Cameron, C.E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348 (2006).
31. Pfeiffer, J.K. & Kirkegaard, K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1, e11 (2005).
32. Vignuzzi, M., wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14, 154-161 (2008).
33. Chumakov, K. & Ehrenfeld, E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis. 47, 1587-1592 (2008).
34. Gustafsson, C., Govindarajan, S. & Minshull, J. Codon bias and heterologous protein expression. Trends Biotechnol. 22, 346-353 (2004).
35. Grantham, R., Gautier, C., Gouy, M., Jacobzone, M. & Mercier, R. Codon catalog usage is a genome strategy modulated for gene expressivity. Nucleic Acids Res. 9, r43-r74 (1981).
36. Sharp, P.M., Tuohy, T.M. & Mosurski, K.R. Codon usage in yeast: cluster analysis clearly differentiates highly and lowly expressed genes. Nucleic Acids Res. 14, 5125-5143 (1986).
37. Carbone, A. Codon bias is a major factor explaining phage evolution in translationally biased hosts. J. Mol. Evol. 66, 210-223 (2008).
38. Jenkins, G.M. & Holmes, E.C. The extent of codon usage bias in human RNA viruses and its evolutionary origin. Virus Res. 92, 1-7 (2003).
39. Shackelton, L.A., Parrish, C.R. & Holmes, E.C. Evolutionary basis of codon usage and nucleotide composition bias in vertebrate DNA viruses. J. Mol. Evol. 62, 551-563 (2006).
40. Plotkin, J.B. & Dushoff, J. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. Proc. Natl. Acad. Sci. USA 100, 7152-7157 (2003).
41. Stephens, C.R. & waelbroeck, H. Codon bias and mutability in HIV sequences. J. Mol. Evol. 48, 390-397 (1999).
42. Burns, C.C. et al. Modulation of poliovirus replicative fitness in HeLa cells by deopti-mization of synonymous codon usage in the capsid region. J. Virol. 80, 3259-3272 (2006).
43. Burns, C.C. et al. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol. 83, 9957-9969 (2009).
44. Mueller, S., Papamichail, D., Coleman, J.R., Skiena, S. & wimmer, E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80, 9687-9696 (2006).
45. Coleman, J.R. et al. Virus attenuation by genome-scale changes in codon pair bias. Science 320, 1784-1787 (2008).
46. Carthew, R.w. & Sontheimer, E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655 (2009).
47. Haasnoot, J., westerhout, E.M. & Berkhout, B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 25, 1435-1443 (2007).
48. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
49. Gottwein, E. & Cullen, B.R. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 3, 375-387 (2008).
50. Lagos-Quintana, M. et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 735-739 (2002).
51. Brown, B.D. & Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10, 578-585 (2009).
52. Brown, B.D., Venneri, M.A., Zingale, A., Sergi Sergi, L. & Naldini, L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591 (2006).
53. Kelly, E.J., Hadac, E.M., Greiner, S. & Russell, S.J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14, 1278-1283 (2008).
54. Cawood, R. et al. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog. 5, e1000440 (2009).
55. Ylösmäki, E. et al. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific microRNA. J. Virol. 82, 11009-11015 (2008).
56. Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K. & Andino, R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4, 239-248 (2008).
57. Perez, J.T. et al. MicroRNA-mediated species-specific attenuation of influenza A virus. Nat. Biotechnol. 27, 572-576 (2009).
58. Iuchi, S. Three classes of C2H2 zinc finger proteins. Cell. Mol. Life Sci. 58, 625-635 (2001).
59. wright, D.A. et al. Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly. Nat. Protoc. 1, 1637-1652 (2006).
60. Dhanasekaran, M., Negi, S. & Sugiura, Y. Designer zinc finger proteins: tools for creating artificial DNA-binding functional proteins. Acc. Chem. Res. 39, 45-52 (2006).
61. Porteus, M. Design and testing of zinc finger nucleases for use in mammalian cells. Methods Mol. Biol. 435, 47-61 (2008).
62. Smith, J. et al. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res. 28, 3361-3369 (2000).
63. Mani, M., Smith, J., Kandavelou, K., Berg, J.M. & Chandrasegaran, S. Binding of two zinc finger nuclease monomers to two specific sites is required for effective double-strand DNA cleavage. Biochem. Biophys. Res. Commun. 334, 1191-1197 (2005).
64. Papworth, M. et al. Inhibition of herpes simplex virus 1 gene expression by designer zinc-finger transcription factors. Proc. Natl. Acad. Sci. USA 100, 1621-1626 (2003).
65. Mino, T. et al. Inhibition of DNA replication of human papillomavirus by artificial zinc finger proteins. J. Virol. 80, 5405-5412 (2006).
66. Mino, T., Mori, T., Aoyama, Y. & Sera, T. Inhibition of human papillomavirus replication by using artificial zinc-finger nucleases. Nucleic Acids Symp. Ser. (Oxf) 52, 185-186 (2008).
67. Fields, B.N., Knipe, D.M., Howley, P.M. & Griffin, D.E. Fields Virology 4th edn (Lippincott williams & wilkins, Philadelphia, 2001).
68. Zhu, Z., Zheng, T., Lee, C.G., Homer, R.J. & Elias, J.A. Tetracycline-controlled tran-scriptional regulation systems: advances and application in transgenic animal modeling. Semin. Cell Dev. Biol. 13, 121-128 (2002).
69. Pruett-Miller, S.M., Reading, D.w., Porter, S.N. & Porteus, M.H. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet. 5, e1000376 (2009).